The on-market immune checkpoint inhibitors including programmed cell death protein-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have shown efficacy with durable responses in some NSCLC patients (4, 5). This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.